Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

80.60USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$80.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
729,390
52-wk High
$81.22
52-wk Low
$37.39

Latest Key Developments (Source: Significant Developments)

Exact Sciences Says Enter Agreement Through 2021 With Pfizer To Co-Promote Cologuard
Wednesday, 22 Aug 2018 12:08pm EDT 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES SAYS CO, PFIZER ENTER INTO AGREEMENT THROUGH 2021 TO CO-PROMOTE COLOGUARD, A STOOL DNA SCREENING TEST FOR COLORECTAL CANCER.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL CO-PROMOTE COLOGUARD WITH CO BEGINNING IN Q4 2018.EXACT SCIENCES SAYS AS PER AGREEMENT, CO WILL MAINTAIN RESPONSIBILITY FOR ALL ASPECTS OF MANUFACTURING & LABORATORY OPERATIONS OF COLOGUARD.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL SHARE GROSS PROFITS & MARKETING EXPENSES EQUALLY ABOVE AN AGREED UPON BASELINE.  Full Article

Exact Sciences reports Q1 Loss Per Share of $0.33
Thursday, 26 Apr 2018 04:05pm EDT 

April 26 (Reuters) - Exact Sciences Corp ::Q1 LOSS PER SHARE $0.33.Q1 REVENUE $90.3 MILLION VERSUS I/B/E/S VIEW $86.9 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.FOR Q2, COMPANY ANTICIPATES COMPLETING 220,000-230,000 COLOGUARD TESTS.  Full Article

Exact Sciences Q4 Loss Per Share $0.18
Thursday, 22 Feb 2018 04:05pm EST 

Feb 22 (Reuters) - Exact Sciences Corp ::COLOGUARD® REVENUE INCREASED 168 PERCENT TO $266 MILLION.Q4 LOSS PER SHARE $0.18.Q4 REVENUE ROSE 148 PERCENT TO $87.4 MILLION.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018..Q4 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $85.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025
Thursday, 11 Jan 2018 04:01pm EST 

Jan 11 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
Wednesday, 10 Jan 2018 08:09am EST 

Jan 10 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION.  Full Article

Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln
Monday, 18 Dec 2017 09:11am EST 

Dec 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING.EXACT SCIENCES - ON DEC. 15, UNIT ENTERED LOAN AGREEMENT FOR A NON-REVOLVING CONSTRUCTION LOAN OF UP TO $25.6 MILLION.  Full Article

Exact Sciences reports qtrly loss per share of $0.23
Monday, 30 Oct 2017 04:05pm EDT 

Oct 30 (Reuters) - Exact Sciences Corp ::Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent.Exact Sciences Corp sees 2017 revenue of $254 million to $257 million.  Full Article

Exact Sciences posts Q2 loss per share $0.27
Tuesday, 25 Jul 2017 04:05pm EDT 

July 25 (Reuters) - Exact Sciences Corp :Q2 loss per share $0.27.Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $230 million to $240 million.Q2 revenue $57.6 million versus I/B/E/S view $49.8 million.FY2017 revenue view $211.2 million -- Thomson Reuters I/B/E/S.Exact Sciences Corp - anticipates completing at least 150,000 cologuard tests during Q3 of 2017.  Full Article

Exact Sciences laboratories enters national ancillary provider participation agreement with Unitedhealthcare Insurance
Wednesday, 5 Jul 2017 09:01am EDT 

July 5 (Reuters) - Exact Sciences Corp ::Exact Sciences Corp -Exact Sciences Laboratories entered national ancillary provider participation agreement with Unitedhealthcare Insurance for cologuard.Exact Sciences Corp - ‍exact and Aetna recently amended that agreement to include Aetna's commercial lines of business, effective July 15, 2017​.Exact Sciences Corp - additional terms of unitedhealthcare agreement are not disclosed .Exact Sciences Corp - additional terms of Aetna agreement, as amended, are not disclosed.  Full Article

Exact Sciences says offering of 7 mln common shares priced at $35 per share
Wednesday, 7 Jun 2017 07:46am EDT 

June 7 (Reuters) - Exact Sciences Corp :Exact sciences announces pricing of public offering of common stock.Says offering of 7.00 million common shares priced at $35.00per share.  Full Article

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.